Role of chemotherapy in the management of ovarian cancer

Expert Review of Anticancer Therapy

Volumn 2, Issue 1, 2002, Pages 90-96

  Markman, Maurie ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alkylating agents; Carboplatin; Cisplatin; Intraperitoneal chemotherapy; Ovarian cancer; Taxanes

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ALTRETAMINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; GEMCITABINE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; THIOTEPA; TOPOTECAN; UNINDEXED DRUG;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; MEDICAL DECISION MAKING; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; REVIEW; SYMPTOMATOLOGY; TREATMENT PLANNING; TUMOR RESISTANCE; VOMITING;

EID: 0036080980     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.1.90     Document Type: Review

References (43)

1. Epithelial carcinoma of the ovary: Current strategies
2. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy
3. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patent data from 37 randomized trials
4. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized Phase III study of the National Cancer Institute Cancer Clinical Trials Group
5. Improved therapeutic index of carboplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a Phase III randomized trial in stages III and IV ovarian cancer
6. Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
7. Phase II trial of paclitxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study
8. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
9. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
10. Paclitaxel delivered as a 3-hour infusion with cisplatin in patients with gynecologic cancer: Unexpected incidence of neurotoxicity
11. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
12. Randomized Phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/Pac in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
13. Cisplatin/paclitaxel vs. carboplatin/ paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study Group trial
14. Phase III randomized study of cisplatin vs. paclitaxel vs. cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study
15. Randomised trial of paclitaxed (PTX) and carboplatin (CBDCA) vs. a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin & cisplatin): The Third International Collaborative Ovarian Neoplasm study (ICON3)
16. Epirubicin/paclitaxel/carboplatin (TEC) vs. paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages Ib-IV
17. Preliminary results of the SCOTROC Trial: A Phase III comparison of pacilitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC)
18. Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery
19. Second-line treatment of ovarian cancer
20. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
21. Interferon-gamma in the first-line therapy of ovarian cancer: A randomized Phase III trial
22. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study
23. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
24. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group Trial (DACOVA)
25. A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma
26. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
27. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: Relevance to therapy and new drug testing
28. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
29. Topotecan versus paclitaxel for treatment of recurrent epithelial ovarian cancer
30. Oral etoposide is active against platinum-resistant epithelial ovarian cancer
31. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
32. Phase II study of gemcitabine (2′,2′- difluorodeoxycytidine) in previously treated ovarian cancer patients
33. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease
34. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer
35. A Phase II study with epirubicin as second-line treatment of patients with advanced epithelial ovarian cancer
36. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer. Activity in platinum-resistant disease
37. Intraperitoneal therapy of ovarian cancer
38. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity
39. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with ip. chemotherapy
40. Five year survival after second-line cisplatin-based ip. chemotherapy for advanced ovarian cancer
41. Impact on survival of surgically defined favorable responses to salvage ip. chemotherapy in small-volume residual ovarian cancer
42. Intraperitoneal cisplatin plus iv. cyclophosphamide versus iv. cisplatin plus iv. cyclophosphamide for state III ovarian cancer
43. Phase III trial of standard-dose iv. cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by iv. paclitaxel and ip. cisplatin in small-volume stage III ovarian carcinoma: An intergroup Oncology Group, Southwestern Oncology Group and Eastern Co-operative Oncology Group